Blancou Philippe, Mallone Roberto, Martinuzzi Emanuela, Sévère Sabine, Pogu Sylvie, Novelli Giulia, Bruno Graziella, Charbonnel Bernard, Dolz Manuel, Chaillous Lucy, van Endert Peter, Bach Jean-Marie
Immuno-Endocrinology Unité Mixte de Recherche 707, Institut National de la Recherche Agronomique/Ecole Nationale Vétérinaire de Nantes/Université, Nantes, France.
J Immunol. 2007 Jun 1;178(11):7458-66. doi: 10.4049/jimmunol.178.11.7458.
Type 1 diabetes (T1D) results from the autoimmune destruction of pancreatic beta cells. CD8(+) T cells have recently been assigned a major role in beta cell injury. Consequently, the identification of autoreactive CD8(+) T cells in humans remains essential for development of therapeutic strategies and of assays to identify aggressive cells. However, this identification is laborious and limited by quantities of human blood samples available. We propose a rapid and reliable method to identify autoantigen-derived epitopes recognized by human CD8(+) T lymphocytes in T1D patients. Human histocompatibility leukocyte Ags-A0201 (HLA-A0201) transgenic mice were immunized with plasmids encoding the T1D-associated autoantigens: 65 kDa glutamic acid decarboxylase (GAD) or insulinoma-associated protein 2 (IA-2). Candidate epitopes for T1D were selected from peptide libraries by testing the CD8(+) reactivity of vaccinated mice. All of the nine-candidate epitopes (five for GAD and four for IA-2) identified by our experimental approach were specifically recognized by CD8(+) T cells from newly diagnosed T1D patients (n = 19) but not from CD8(+) T cells of healthy controls (n = 20). Among these, GAD(114-123), GAD(536-545) and IA-2(805-813) were recognized by 53%, 25%, and 42% of T1D patients, respectively.
1型糖尿病(T1D)是由胰腺β细胞的自身免疫性破坏引起的。最近研究发现,CD8(+) T细胞在β细胞损伤中起主要作用。因此,鉴定人类自身反应性CD8(+) T细胞对于开发治疗策略和鉴定侵袭性细胞的检测方法仍然至关重要。然而,这种鉴定工作繁琐,并且受限于可用的人类血液样本数量。我们提出了一种快速可靠的方法,用于鉴定T1D患者中人类CD8(+) T淋巴细胞识别的自身抗原衍生表位。用编码T1D相关自身抗原的质粒免疫人类组织相容性白细胞抗原-A0201(HLA-A0201)转基因小鼠:65 kDa谷氨酸脱羧酶(GAD)或胰岛瘤相关蛋白2(IA-2)。通过测试接种疫苗小鼠的CD8(+)反应性,从肽库中选择T1D的候选表位。我们的实验方法鉴定出的所有九个候选表位(五个针对GAD,四个针对IA-2)均被新诊断的T1D患者(n = 19)的CD8(+) T细胞特异性识别,但未被健康对照者(n = 20)的CD8(+) T细胞识别。其中,GAD(114 - 123)、GAD(536 - 545)和IA-2(805 - 813)分别被53%、25%和42%的T1D患者识别。